Program
vsv-gp BI 1831169
Its studies are led by Boehringer Ingelheim.
Furthest: phase 1, since Dec 10, 20212 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 20 open or running | phase 1since Dec 10, 2021 | Dec 10, 2021 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 10, 2021First study: phase 1 study in Solid TumorsFirst studyNCT05155332 · 190 enrolled · United States, Australia, Austria and more
- Sep 15, 2025Phase 1 study in Solid TumorsNCT07176975 · 46 enrolled · Japan
- Nov 10, 2026Primary completion moved from 2027-12-13 to 2028-07-18Date moved laterphase 1 · +7 months · NCT05155332
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07176975Solid Tumors · Japan | 1 | Suspended | Dec 19, 2028 | 46 |
| NCT05155332Solid Tumors · United States, Australia, Austria and more | 1 | Suspended | Jul 18, 2028 | 190 |
How it is read
Names in the registry
- “BI 1831169”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.